Clinical trials are organized studies that are designed to determine the safety and effectiveness of a new treatment. The most promising agents and therapies are selected for inclusion in the treatment studies at the Methodist Neuroscience Institute.
For current Clinical Trials, please contact:
Rexann G. Pickering, Ph.D., R.N.
Administrator, Human Protection
MHIRB Administration
1325 Eastmoreland Ave., Suite 574
Memphis, Tennessee 38104
Phone: 901.516.2323
Fax: 901.516-2456
|
To view this site, you need to have Flash Player 10.0 or newer installed. Click here to get the latest Adobe Flash player.
|
|
2008-034 |
| A randomized, open-label, 3-arm Phase II study assessing the anti-tumor activity of BIBW 2992 among patients with recurrent GBM. |
2008-038 |
| Cilengitide for subjects with newly diagnosed glioblastoma multiforme and methylated MGMT gene promoter – a multicenter, open-label, controlled phase III study, testing cilengitide in combination with standard treatment (temozolomide with concomitant radiation therapy, followed by temozolomide maintenance therapy) versus standard treatment alone (CENTRIC). |
|
|
|
